WebCisplatin is a potent and valuable chemotherapy agent used to treat a broad spectrum of malignancies. Renal tubular dysfunction and a cumulative impairment in kidney function, as manifested by a decline in the glomerular filtration rate (GFR), can be dose limiting. WebAbstract Cisplatin (DDP) is a common therapeutic option for non-small cell lung carcinoma (NSCLC). However, some patients fail to respond to the DDP chemotherapy. ... Targeted therapy for cisplatin-resistant lung cancer via aptamer-guided nano-zinc carriers containing USP14 siRNA. Xinmin Zhao, ... Some chronic toxicity was observed in the 10 mg ...
Short Hydration in Chemotherapy Containing Cisplatin (≥75 mg/m
WebDec 1, 2024 · Dose adjustments for both docetaxel and cisplatin were performed according to pre-defined criteria for each type of toxicity (mainly grade 4 neutropenia and grade 3–4 neuropathy). Two dose reductions were allowed for DC75 (first to 60 mg/m 2, second to 50 mg/m 2), but only 1 reduction was allowed for DC60 and DCM therapy (to 50 mg/m 2). … WebNational Center for Biotechnology Information flood clean up lismore
Bleomycin etoposide and cisplatin regimen - UpToDate
WebPulmonary toxicity of cytotoxic agents Platinum compounds The administration of cisplatin and carboplatin, the 2 most commonly used platinum derivative agents, can lead to … WebSep 4, 2013 · Short hydration is safe and reduces the frequency of severe renal toxicities in regimens containing cisplatin (≥75 mg/m 2) for the treatment of patients with lung cancer. Cisplatin labels with regard to hydration should accept short- and lower-volume hydration as an option based on the result of the present study. Funding WebJun 1, 2016 · The carboplatin-docetaxel arm had a more favourable toxicity profile and a significant number of patients withdrew from the cisplatin-docetaxel doublet due to grade 3–4 emesis ( Greco et al., 2000 ). Other studies have observed the efficacy and tolerability of platinum-gemcitabine regimens in CUP. great longstone village shop